| Not Yet Recruiting | A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adul NCT07513129 | M.D. Anderson Cancer Center | Phase 1 |
| Not Yet Recruiting | Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells NCT07220993 | Baylor College of Medicine | Phase 1 |
| Recruiting | Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma NCT07300683 | University College, London | Phase 1 |
| Recruiting | A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Ped NCT06561074 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukem NCT06514794 | Wugen, Inc. | Phase 2 |
| Recruiting | Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblasti NCT06390319 | St. Jude Children's Research Hospital | Phase 2 |
| Recruiting | Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transp NCT06686108 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 2 |
| Recruiting | Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymp NCT06420076 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies NCT06316427 | Beijing GoBroad Hospital | Phase 1 / Phase 2 |
| Recruiting | Universal 4SCAR7U Targeting CD7-positive Malignancies NCT05995028 | Shenzhen Geno-Immune Medical Institute | Phase 1 |
| Recruiting | Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL NCT05289687 | Eastern Cooperative Oncology Group | Phase 2 |
| Recruiting | Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL NCT04972942 | New York Medical College | Phase 1 |
| Recruiting | Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL NCT05679895 | OneChain Immunotherapeutics | Phase 1 |
| Unknown | CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia NCT05596266 | Xuanwu Hospital, Beijing | Phase 1 |
| Enrolling By Invitation | A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 NCT05509855 | Wugen, Inc. | — |
| Completed | Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies NCT05290155 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 1 |
| Recruiting | Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients NCT05376111 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Unknown | NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL NCT05277753 | Shenzhen Geno-Immune Medical Institute | Phase 1 |
| Terminated | XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia NCT05038644 | Ehab L Atallah | Phase 1 |
| Completed | A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refrac NCT04984356 | Wugen, Inc. | Phase 1 |
| Unknown | Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia NCT05832125 | Versailles Hospital | — |
| Withdrawn | A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL NCT04860817 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | EARLY_Phase 1 |
| Terminated | Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia NCT05032599 | Beijing Boren Hospital | Phase 1 |
| Recruiting | Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells NCT03690011 | Baylor College of Medicine | Phase 1 |
| Unknown | Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies NCT04594135 | iCell Gene Therapeutics | Phase 1 |
| Unknown | Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances NCT04934774 | iCell Gene Therapeutics | Phase 1 |
| Unknown | Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies NCT04033302 | Shenzhen Geno-Immune Medical Institute | Phase 1 / Phase 2 |
| Recruiting | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Anti NCT03081910 | Baylor College of Medicine | Phase 1 |
| Completed | A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL NCT02518113 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Completed | Hyper-CVAD Treatment of Adult T-cell Acute Lymphoblastic Leukemia in Sweden. NCT01950286 | Region Örebro County | — |